RxDoctor Payments Data

Timothy Tang, MD

Internal Medicine · Houston, TXNPI 1093805046

Payments from drug & device makers

$2,044in general payments, 2019–2025

Across 106 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$479
  • Lilly USA, LLC$300
  • Gilead$176
  • Exact Sciences$168
  • AstraZeneca$164
  • AbbVie$155
  • plus $602 from 15 others

What the payments were for

  • Food & beverage$2,03099%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,044 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$50,916
Medicare patients
98
Services billed
530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol57$56,260
TrulicityDulaglutide45$48,942
TradjentaLinagliptin29$32,034
JardianceEmpagliflozin18$29,639
EliquisApixaban26$22,106
OzempicSemaglutide14$20,459
JanuviaSitagliptin Phosphate13$16,016
VascepaIcosapent Ethyl19$14,322
Valsartan108$2,457
Atorvastatin Calcium349$1,836
Ipratropium Bromide76$1,571
Gabapentin92$1,564
Metoprolol Succinate150$1,350
Tramadol Hcl82$1,204
Losartan Potassium168$1,192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$164$56,26057 claims
Lilly USA, LLCTrulicity$300$48,94245 claims
PfizerEliquis$25$22,10626 claims
Novo NordiskOzempic$479$20,45914 claims
MerckJanuvia$14$16,01613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →